The MLNM acquisition perhaps makes more sense when one considers how much “catching up” Japan’s Big Pharma has to do to reach parity with its US and European counterparts. #msg-26484658 is a good quick read on the topic, IMO.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”